Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2011 Jan 20;10(3):550–557. doi: 10.1158/1535-7163.MCT-10-0571

Figure 5.

Figure 5

CRL8799 normal breast cancer cells, CRL2335, MDA-MB-468 TNBC cells were treated with cisplatin, TRAIL or cisplatin plus TRAIL as shown in Fig.2 . Whole cell extracts were prepared and examined the expression of Survivin, Bcl-2 and Bcl-xl by Western blotting (Fig. 5A). Equal protein loading was compared with that of GAPDH. (B) Effect of Survivin knockdown on TRAIL-induced cell death. CRL2335 TNBC cells were transfected with either Survivin siRNA or random siRNA. After 48h of transfection, cells were treated with or without TRAIL for additional 24h. Whole cell extracts were prepared and the expression of Survivin, caspases -3 and -8 were examined by Western blotting. Equal protein loading was compared with that of GAPDH. (C) Under similar conditions cell viability was also assessed using trypan blue exclusion method.